Research progress of AFP in the diagnosis and therapy of hepatocellular carcinoma.

Liyuan Qian; Changfei LI; Yunjing Luo; Songdong Meng

Return

Research progress of AFP in the diagnosis and therapy of hepatocellular carcinoma.

Author: Liyuan QIAN ¹ ; Changfei LI ² ; Yunjing LUO ¹ ; Songdong MENG ²
Author Information

1. Beijing Key Laboratory of Environmental and Viral oncology, College of Environmental and Energy Engineering, Beijing University of Technology, Beijing 100124, China.
2. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Publication Type:Journal Article
Keywords: HCC treatment; alpha-fetoprotein; clinical diagnosis; hepatocellular carcinoma; serological markers
MeSH: Biomarkers, Tumor/genetics*; Carcinoma, Hepatocellular/therapy*; Early Detection of Cancer; Humans; Liver Neoplasms/therapy*; alpha-Fetoproteins
From: Chinese Journal of Biotechnology 2021;37(9):3042-3060
CountryChina
Language:Chinese
Abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths and the fifth most common cancer worldwide. Clinically therapeutic options for HCC are very limited, and the overall survival rate of patients is very low. Therefore, early diagnosis and treatment of HCC have important impact on overall survival of patients. At present, alpha-fetoprotein (AFP) is one of the most widely used serological markers for HCC. Many evidences have shown that as a specific onco-protein, AFP has great research value in the occurrence, development, diagnosis and treatment of HCC. Here, we briefly introduce the molecular mechanism of AFP in the regulation of HCC occurrence and development, and its role in tumor escape from immune surveillance. We focus on the application of AFP as an important HCC target or carcino-embryonic antigen (CEA) in HCC clinical diagnosis and treatment.